Pregnane X receptor mediates dyslipidemia induced by the hiv protease inhibitor amprenavir in mices

Molecular Pharmacology

Volumn 83, Issue 6, 2013, Pages 1190-1199

  Helsley, Robert N ^a   Sui, Yipeng ^a   Ai, Ni ^b   Park, Se Hyung ^a   Welsh, William J ^b   Zhou, Changcheng ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PREGNANE X RECEPTOR; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; LIPID METABOLISM; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

ANIMALS; BINDING SITES; CARBAMATES; CELL LINE; DYSLIPIDEMIAS; GENE EXPRESSION; HIV PROTEASE INHIBITORS; HUMANS; LIPIDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR DOCKING SIMULATION; RECEPTORS, STEROID; SULFONAMIDES;

EID: 84877793875     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.085753     Document Type: Article

References (56)

1. Ables GP, Yang KJ, Vogel S, Hernandez-Ono A, Yu S, Yuen JJ, Birtles S, Buckett LK, Turnbull AV, and Goldberg IJ et al. (2012) Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res 53:2364-2379.
2. Abumrad NA and Davidson NO (2012) Role of the gut in lipid homeostasis. Physiol Rev 92:1061-1085.
3. Anderson RA and Sando GN (1991) Cloning and expression of cDNA encoding human lysosomal acid lipase/cholesteryl ester hydrolase. Similarities to gastric and lingual lipases. J Biol Chem 266:22479-22484. (Pubitemid 21908678)
4. Barry M, Mulcahy F, Merry C, Gibbons S, and Back D (1999) Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36:289-304. (Pubitemid 29201737)
5. Bhaskaran K, Hamouda O, Sannes M, Boufassa F, Johnson AM, Lambert PC, and Porter K; CASCADE Collaboration (2008) Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 300:51-59. (Pubitemid 351920404)
6. Blumberg B, Sabbagh W, Jr, Juguilon H, Bolado J, Jr, van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205. (Pubitemid 28496264)
7. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, and Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58. (Pubitemid 28190689)
8. Carriere F, Barrowman JA, Verger R, and Laugier R (1993) Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans. Gastroenterology 105:876-888. (Pubitemid 23249500)
9. Cheng J, Krausz KW, Tanaka N, and Gonzalez FJ (2012) Chronic exposure to rifaximin causes hepatic steatosis in pregnane X receptor-humanized mice. Toxicol Sci 129:456-468.
10. de Haan W, de Vries-van der Weij J, Mol IM, Hoekstra M, Romijn JA, Jukema JW, Havekes LM, Princen HM, and Rensen PC (2009) PXR agonism decreases plasma HDL levels in ApoE3-Leiden.CETP mice. Biochim Biophys Acta 1791:191-197.
11. Distler O, Cooper DA, Deckelbaum RJ, and Sturley SL (2001) Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care 4:99-103. (Pubitemid 34755450)
12. Du H, Heur M, Duanmu M, Grabowski GA, Hui DY, Witte DP, and Mishra J (2001) Lysosomal acid lipase-deficient mice: Depletion of white and brown fat, severe hepatosplenomegaly, and shortened life span. J Lipid Res 42:489-500. (Pubitemid 32366991)
13. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, and Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276:33309-33312.
14. Eirís JM, Lojo S, Del Río MC, Novo I, Bravo M, Pavón P, and Castro-Gago M (1995) Effects of long-term treatment with antiepileptic drugs on serum lipid levels in children with epilepsy. Neurology 45:1155-1157.
15. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte Ad, El-Sadr W, Thiébaut R, De Wit S, Kirk O, and Fontas E et al.; DAD Study Group (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356:1723-1735. (Pubitemid 46658704)
16. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, and Pradier C et al.; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349:1993-2003.
17. Gao J and Xie W (2012) Targeting xenobiotic receptors PXR and CAR for metabolic diseases. Trends Pharmacol Sci 33:552-558.
18. Gargouri Y, Pieroni G, Rivière C, Lowe PA, Saunière JF, Sarda L, and Verger R (1986) Importance of human gastric lipase for intestinal lipolysis: An in vitro study. Biochim Biophys Acta 879:419-423. (Pubitemid 17189929)
19. He J, Gao J, Xu M, Ren S, Stefanovic-Racic M, O'Doherty RM, and Xie W (2013) PXR ablation alleviates diet-induced and genetic obesity and insulin resistance in mice. Diabetes DOI: [published ahead of print].
20. Hoekstra M, Lammers B, Out R, Li Z, Van Eck M, and Van Berkel TJ (2009) Activation of the nuclear receptor PXR decreases plasma LDL-cholesterol levels and induces hepatic steatosis in LDL receptor knockout mice. Mol Pharm 6: 182-189.
21. Horner MA, Pardee K, Liu S, King-Jones K, Lajoie G, Edwards A, Krause HM, and Thummel CS (2009) The Drosophila DHR96 nuclear receptor binds cholesterol and regulates cholesterol homeostasis. Genes Dev 23:2711-2716.
22. Kanebratt KP and Andersson TB (2008) Evaluation of HepaRG cells as an in vitro model for human drug metabolism studies. Drug Metab Dispos 36:1444-1452. (Pubitemid 351929328)
23. Khogali AM, Chazan BI, Metcalf VJ, and Ramsay JHR (1974) Hyperlipidaemia as a complication of rifampicin treatment. Tubercle 55:231-233.
24. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr Rev 23:687-702. (Pubitemid 35191629)
25. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, Jones SA, McKee DD, Oliver BB, Willson TM, and Zetterström RH et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82. (Pubitemid 28053299)
26. Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, and Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV (2010) Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: A case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 170:1228-1238.
27. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, and Sturley SL (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7:1327-1331. (Pubitemid 34007937)
28. Lu Y, Feskens EJ, Boer JM, and Müller M (2010) The potential influence of genetic variants in genes along bile acid and bile metabolic pathway on blood cholesterol levels in the population. Atherosclerosis 210:14-27.
29. Lütjohann D, Hahn C, Prange W, Sudhop T, Axelson M, Sauerbruch T, von Bergmann K, and Reichel C (2004) Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. Int J Clin Pharmacol Ther 42: 307-313. (Pubitemid 38787274)
30. Moreau A, Téruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, Parmentier Y, Sa-Cunha A, Suc B, and Fabre JM et al. (2009) A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 49:2068-2079.
31. Nassir F, Wilson B, Han X, Gross RW, and Abumrad NA (2007) CD36 is important for fatty acid and cholesterol uptake by the proximal but not distal intestine. J Biol Chem 282:19493-19501. (Pubitemid 47100088)
32. Nauli AM, Nassir F, Zheng S, Yang Q, Lo CM, Vonlehmden SB, Lee D, Jandacek RJ, Abumrad NA, and Tso P (2006) CD36 is important for chylomicron formation and secretion and may mediate cholesterol uptake in the proximal intestine. Gastroenterology 131:1197-1207. (Pubitemid 44498699)
33. Park SH, Sui Y, Gizard F, Xu J, Rios-Pilier J, Helsley RN, Han SS, and Zhou C (2012) Myeloid-specific IkB kinase b deficiency decreases atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 32:2869-2876.
34. Payne AW and Glen RC (1993) Molecular recognition using a binary genetic search algorithm. J Mol Graph 11:74-91, 121-123.
35. Périard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, and Darioli R et al. (1999) Atherogenic dyslipidemia in HIVinfected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100:700-705. (Pubitemid 29383638)
36. Pisciotta L, Fresa R, Bellocchio A, Pino E, Guido V, Cantafora A, Di Rocco M, Calandra S, and Bertolini S (2009) Cholesteryl ester storage disease (CESD) due to novel mutations in the LIPA gene. Mol Genet Metab 97:143-148.
37. Sadler BM, Hanson CD, Chittick GE, Symonds WT, and Roskell NS (1999) Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 43:1686-1692. (Pubitemid 29331248)
38. Sadler BM and Stein DS (2002) Clinical pharmacology and pharmacokinetics of amprenavir. Ann Pharmacother 36:102-118. (Pubitemid 34052954)
39. Shafran SD, Mashinter LD, and Roberts SE (2005) The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 6:421-425. (Pubitemid 41723310)
40. Sheriff S, Du H, and Grabowski GA (1995) Characterization of lysosomal acid lipase by site-directed mutagenesis and heterologous expression. J Biol Chem 270: 27766-27772.
41. Sieber MH and Thummel CS (2009) The DHR96 nuclear receptor controls triacylglycerol homeostasis in Drosophila. Cell Metab 10:481-490.
42. Sieber MH and Thummel CS (2012) Coordination of triacylglycerol and cholesterol homeostasis by DHR96 and the Drosophila LipA homolog magro. Cell Metab 15: 122-127.
43. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, and Sosman JM (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257-262. (Pubitemid 32666944)
44. Sui Y, Ai N, Park SH, Rios-Pilier J, Perkins JT, Welsh WJ, and Zhou C (2012) Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect 120:399-405.
45. Sui Y, Xu J, Rios-Pilier J, and Zhou C (2011) Deficiency of PXR decreases atherosclerosis in apoE-deficient mice. J Lipid Res 52:1652-1659.
46. Teupser D, Persky AD, and Breslow JL (2003) Induction of atherosclerosis by low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ mice: Comparison of lesions of the aortic root, brachiocephalic artery, and whole aorta (en face measurement). Arterioscler Thromb Vasc Biol 23:1907-1913. (Pubitemid 37254883)
47. Ueda A, Matsui K, Yamamoto Y, Pedersen LC, Sueyoshi T, and Negishi M (2005) Thr176 regulates the activity of the mouse nuclear receptor CAR and is conserved in the NR1I subfamily members PXR and VDR. Biochem J 388:623-630. (Pubitemid 40839940)
48. Wang W, Prosise WW, Chen J, Taremi SS, Le HV, Madison V, Cui X, Thomas A, Cheng KC, and Lesburg CA (2008) Construction and characterization of a fully active PXR/SRC-1 tethered protein with increased stability. Protein Eng Des Sel 21:425-433. (Pubitemid 351882132)
49. Wire MB, SheltonMJ, and Studenberg S (2006) Fosamprenavir : Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 45:137-168. (Pubitemid 43290828)
50. Zhou C, King N, Chen KY, and Breslow JL (2009a) Activation of PXR induces hypercholesterolemia in wild-type and accelerates atherosclerosis in apoE deficient mice. J Lipid Res 50:2004-2013.
51. Zhou C, Poulton EJ, Grün F, Bammler TK, Blumberg B, Thummel KE, and Eaton DL (2007) The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol 71:220-229. (Pubitemid 46020992)
52. Zhou C, Pridgen B, King N, Xu J, and Breslow JL (2011) Hyperglycemic Ins2AkitaLdlr2/2 mice show severely elevated lipid levels and increased atherosclerosis: A model of type 1 diabetic macrovascular disease. J Lipid Res 52:1483-1493.
53. Zhou C, Tabb MM, Nelson EL, Grün F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, and Thummel KE et al. (2006a) Mutual repression between steroid and xenobiotic receptor and NF-kB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116:2280-2289. (Pubitemid 44162338)
54. Zhou C, Tabb MM, Sadatrafiei A, Grün F, and Blumberg B (2004) Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos 32:1075-1082. (Pubitemid 39287580)
55. Zhou C, Verma S, and Blumberg B (2009b) The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl Recept Signal 7:e001.
56. Zhou J, Zhai Y, Mu Y, Gong H, Uppal H, Toma D, Ren S, Evans RM, and Xie W (2006b) A novel pregnane X receptor-mediated and sterol regulatory elementbinding protein-independent lipogenic pathway. J Biol Chem 281:15013-15020. (Pubitemid 43855205)